Global and USA Typhoid Vi Polysaccharide Vaccine Market Insights, Forecast to 2027

Typhoid Vi polysaccharide vaccine is a vaccine that is administered intramuscularly. It is an active immunization for the prevention of typhoid fever caused by S typhi and is approved for use in persons two years of age or older.

Market Analysis and Insights: Global and USA Typhoid Vi Polysaccharide Vaccine Market
This report focuses on global and USA Typhoid Vi Polysaccharide Vaccine market.
In 2020, the global Typhoid Vi Polysaccharide Vaccine market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% during 2021-2027. In USA the Typhoid Vi Polysaccharide Vaccine market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.

Global Typhoid Vi Polysaccharide Vaccine Scope and Market Size
Typhoid Vi Polysaccharide Vaccine market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Typhoid Vi Polysaccharide Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For USA market, this report focuses on the Typhoid Vi Polysaccharide Vaccine market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in USA.

Segment by Type
Child
Adult

Segment by Application
Government Institution
Private Sector
Other

By Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

By Company
Sanofi Pasteur SA
GSK